The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Hemophilia B Gene Therapy Market Become By 2030 Compared To 2026?

The hemophilia b gene therapy market size has seen significant expansion in recent years. It is anticipated to increase from $0.55 billion in 2025 to $0.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 29.6%. The historical growth can be linked to several factors, including advancements in gene delivery technologies, a deeper understanding of hemophilia b genetics, the expansion of clinical research programs, the increasing burden associated with lifelong replacement therapy, and the presence of specialized treatment centers.

The hemophilia b gene therapy market size is projected to experience substantial growth over the upcoming years. It is forecast to achieve a valuation of **$2.01 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 29.8%**. This expansion during the forecast period is primarily driven by factors such as the increasing approvals of gene therapies, rising investments in treatments for rare diseases, a growing demand for enduring therapeutic results, the enhancement of advanced manufacturing capabilities, and an increase in patient access programs. Furthermore, significant trends anticipated during this period include continued progress in one-time curative therapies, a heightened focus on long-term factor IX expression, ongoing optimization of AAV vector design, the expansion of personalized gene therapy approaches, and improved regulatory harmonization for advanced therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33162&type=smp

What Influential Factors Are Boosting The Hemophilia B Gene Therapy Market Demand?

The hemophilia B gene therapy market is projected to expand due to the increasing volume of gene therapy clinical trials. These trials are research endeavors aimed at assessing the safety, effectiveness, and lasting therapeutic impact of gene-based treatments in human subjects. The growth in gene therapy clinical trials is spurred by greater investment from biopharmaceutical firms, advancements in viral vector technologies, supportive regulatory environments, and the critical need to address rare genetic conditions with significant unmet medical requirements, including hemophilia B. This expanding landscape of clinical trials benefits hemophilia B gene therapy by providing established clinical development routes, regulatory expertise, and manufacturing capabilities pertinent to in vivo gene delivery methods. For example, in January 2026, the Bioindustry Association (BIA), a national trade association based in the UK, reported 193 ongoing advanced therapy clinical trials in the UK, a figure broadly comparable to 2024. Over half of these trials were in early stages, approximately 80% were commercially sponsored, and more than 80% focused on gene therapies, divided equally between ex vivo and in vivo approaches. Consequently, the escalation in cell and gene therapy clinical trials is propelling the hemophilia B gene therapy market’s expansion. Rising Adoption Of Personalized Medicine Is Fueling The Growth Of The Market Due To Its Role In Enabling Tailored Treatments, Patient Stratification, And Improved Therapeutic Outcomes

What Are The Core Segment Classifications In The Hemophilia B Gene Therapy Market?

The hemophilia b gene therapy market covered in this report is segmented –

1) By Therapy: Adeno-Associated Viral (AAV) Vectors; Lentiviral Vectors; Retroviral Vectors

2) By Disease Severity: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B

3) By Treatment Type: On-Demand; Cure; Prophylaxis

4) By Patient Age Group: Geriatric; Adults; Pediatric

5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies

Subsegments:

1) By Adeno-Associated Viral Vectors: Single-Stranded Adeno-Associated Viral Vectors; Self-Complementary Adeno-Associated Viral Vectors; Tissue Specific Promoter Adeno-Associated Viral Vectors; Capsid Modified Adeno-Associated Viral Vectors

2) By Lentiviral Vectors: Integrating Lentiviral Vectors; Non-Integrating Lentiviral Vectors; Self-Inactivating Lentiviral Vectors; Pseudotyped Lentiviral Vectors

3) By Retroviral Vectors: Gamma Retroviral Vectors; Alpha Retroviral Vectors; Moloney Murine Leukemia Virus Retroviral Vectors; Spumaretroviral Vectors

Which Trends Are Contributing To Changes In The Hemophilia B Gene Therapy Market?

Companies operating in the hemophilia B gene therapy market are increasingly concentrating on advancements in next-generation gene delivery platforms, particularly optimized adeno-associated virus (AAV)–based vector systems, to enhance therapeutic efficacy and safety. These optimized AAV-based vector systems function as advanced viral delivery platforms, enabling the efficient and controlled transfer of functional clotting factor IX genes into target hepatocytes, which supports long-term endogenous factor production. For example, in May 2023, CSL Behring GmbH, a Germany-based biotechnology company, obtained European Commission approval for HEMGENIX, the initial gene therapy sanctioned for treating hemophilia B. HEMGENIX is prescribed for adult patients with severe or moderate hemophilia B who have no history of factor IX inhibitors, with the goal of reducing or eliminating the need for routine factor IX prophylaxis. Results from the pivotal HOPE-B clinical study showed that a substantial number of treated patients no longer required regular factor IX infusions, demonstrating sustained therapeutic benefit and underscoring the potential of next-generation AAV-based gene therapies in managing the disease long-term.

Who Are The Firms Contributing To The Hemophilia B Gene Therapy Market Ecosystem?

Major companies operating in the hemophilia b gene therapy market are REGENXBIO Inc., Pfizer Inc., Bayer Aktiengesellschaft (Bayer AG), Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring LLC, Lonza Group AG, Alnylam Pharmaceuticals Inc., GenScript ProBio LLC, Ultragenyx Pharmaceutical Inc., Takara Bio Inc., Sangamo Therapeutics Inc., Precision BioSciences Inc., Synthego Corporation, MaxCyte Inc., uniQure N.V., Freeline Therapeutics Ltd., Be Biopharma Inc., Asklepios BioPharmaceutical Inc., Cellectis S.A.

Access The Complete Hemophilia B Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/hemophilia-b-gene-therapy-market-report

What Is The Largest Regional Market In The Hemophilia B Gene Therapy Market?

North America was the largest region in the hemophilia b gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemophilia b gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Hemophilia B Gene Therapy Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model